Cargando…

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men

PURPOSE: To evaluate pharmacokinetics, safety, and tolerability of abiraterone acetate (AA) in healthy men. METHODS: Two phase I studies (dose-escalation study and dose-proportionality study) were conducted in healthy men aged 18–55 years. All subjects received 4 consecutive single doses of AA (250,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acharya, M., Bernard, A., Gonzalez, M., Jiao, J., De Vries, R., Tran, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362727/ https://www.ncbi.nlm.nih.gov/pubmed/22526411 http://dx.doi.org/10.1007/s00280-012-1865-3

Ejemplares similares

Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets
por: Feng, Zeying, et al.
Publicado: (2022)

Abiraterone Acetate
Publicado: (2012)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study
por: Wu, Zhao-xin, et al.
Publicado: (2023)

Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies
por: Goldwater, Ronald, et al.
Publicado: (2017)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
por: Tachibana, Masaya, et al.
Publicado: (2023)

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
por: Attard, Gerhardt, et al.
Publicado: (2019)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation
por: Liu, Yuanfen, et al.
Publicado: (2022)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
por: Trivedi, Ashit, et al.
Publicado: (2022)

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial
por: Deng, Kunhong, et al.
Publicado: (2022)

Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects
por: Luckey, Alison, et al.
Publicado: (2023)

The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug–Drug Interaction in Healthy Participants
por: Marino, Rose, et al.
Publicado: (2023)

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
por: Chi, Kim N, et al.
Publicado: (2023)

Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial
por: Luo, Yeping, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
por: Papi, Alberto, et al.
Publicado: (2020)

Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study
por: Trivedi, Ashit, et al.
Publicado: (2022)

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects
por: Liu, Jian, et al.
Publicado: (2023)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2014)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
por: Kim, Seokuee, et al.
Publicado: (2014)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
por: Smith, William B, et al.
Publicado: (2012)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
por: Locati, Laura D., et al.
Publicado: (2021)

Treatment gains from the “sandwich method” of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience
por: Wang, Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q5gn1cvqjsv3fih4317ji4t0ih